Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
{{output}}
The recent FDA approval of Rezdiffra (resmetirom), an oral partial agonist of the thyroid hormone receptor-beta (THR-beta), for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis, has challenged conventional a... ...
